Joseph Eiden

FluGen (United States) — United States

Immunology and Microbiology · Life Sciences

28h-index3.2kcitations68works11.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bacterial Infections and Vaccines(25), Pneumonia and Respiratory Infections(17), Antimicrobial Resistance in Staphylococcus(11), Viral gastroenteritis research and epidemiology(11), Allergic Rhinitis and Sensitization(8)

Publications67 total

Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial
The Lancet Infectious Diseases·2024· 11 cited
Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older
Vaccine·2022· 2 cited
Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data
Infectious Diseases and Therapy·2020· 4 citedOpen Access
Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag)
Open Forum Infectious Diseases·2019· 20 citedOpen Access
2748. Single Intranasal (IN) Dose of M2SR (M2-Deficient Single Replication) Live Influenza Vaccine Protects Adults Against Subsequent Challenge with a Substantially Drifted H3N2 Strain
Open Forum Infectious Diseases·2019· 2 citedOpen Access
S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine
Journal of Infection·2019· 8 cited
2722. Effects of Sex, Age, and Race on Immunogenicity of MenB-FHbp, a Bivalent Meningococcal B Vaccine: A Pooled Evaluation of Clinical Trial Data
Open Forum Infectious Diseases·2019Open Access
A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec
mSphere·2018· 10 citedOpen Access
Safety, tolerability, and immunogenicity of a novel 4-antigen <i>Staphylococcus aureus</i> vaccine (SA4Ag) in healthy Japanese adults
Human Vaccines & Immunotherapeutics·2018· 14 citedOpen Access
A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of a Four-Antigen Vaccine for Staphylococcus Aureus in Adults Prior to Open Posterior Spinal Fusion Surgery
The Spine Journal·2017· 1 cited
Meningococcal carriage in Dutch adolescents and young adults; a cross-sectional and longitudinal cohort study
Clinical Microbiology and Infection·2017· 38 citedOpen Access
SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies
Vaccine·2017· 86 cited
Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study
Vaccine·2016· 62 citedOpen Access
Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial
Vaccine·2016· 53 citedOpen Access
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial
The Lancet Infectious Diseases·2016· 39 citedOpen Access
Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study
Journal of Infection·2016· 11 cited
<i>Staphylococcus aureus</i>: the current state of disease, pathophysiology and strategies for prevention
Expert Review of Vaccines·2016· 148 cited
Letter to the editor: Importance of serum bactericidal activity for estimating the breadth of protection for new meningococcal vaccines
Eurosurveillance·2016· 1 citedOpen Access
A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents
The Pediatric Infectious Disease Journal·2016· 40 cited
A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults
Vaccine·2016· 68 cited
page 1 of 4Next →

Frequent Co-authors

Annaliesa S. Anderson(16), Kathrin U. Jansen(16), Qin Jiang(9), John L. Perez(9), Kathrin U. Jansen(8), Thomas R. Jones(8), William C. Gruber(8), Shannon L. Harris(7), David Cooper(6), James Baber(6), Laura J. York(6), Gary Van Nest(5), Edward T. Zito(5), Louise Pedneault(5), Alejandra Gurtman(4), Peter Richmond(4), Helen Marshall(4), Joseph M. Severs(4), Nicholas Kitchin(4), Prakash Bhuyan(4)